DK1052974T3 - Farmaceutisk sammensætning indeholdende epothilon - Google Patents

Farmaceutisk sammensætning indeholdende epothilon

Info

Publication number
DK1052974T3
DK1052974T3 DK99907491T DK99907491T DK1052974T3 DK 1052974 T3 DK1052974 T3 DK 1052974T3 DK 99907491 T DK99907491 T DK 99907491T DK 99907491 T DK99907491 T DK 99907491T DK 1052974 T3 DK1052974 T3 DK 1052974T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
composition containing
containing epothilone
epothilone
pharmaceutical
Prior art date
Application number
DK99907491T
Other languages
English (en)
Inventor
Hoogevest Peter Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1052974(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9802451.6A external-priority patent/GB9802451D0/en
Priority claimed from GBGB9813646.8A external-priority patent/GB9813646D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1052974T3 publication Critical patent/DK1052974T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99907491T 1998-02-05 1999-02-03 Farmaceutisk sammensætning indeholdende epothilon DK1052974T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802451.6A GB9802451D0 (en) 1998-02-05 1998-02-05 Organic compounds
GBGB9813646.8A GB9813646D0 (en) 1998-06-24 1998-06-24 Organic compounds
PCT/EP1999/000702 WO1999039694A2 (en) 1998-02-05 1999-02-03 Compositions containing organic compounds

Publications (1)

Publication Number Publication Date
DK1052974T3 true DK1052974T3 (da) 2009-08-10

Family

ID=26313062

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99907491T DK1052974T3 (da) 1998-02-05 1999-02-03 Farmaceutisk sammensætning indeholdende epothilon

Country Status (37)

Country Link
US (5) US20030203876A1 (da)
EP (1) EP1052974B1 (da)
JP (2) JP4644364B2 (da)
KR (3) KR20080016756A (da)
CN (2) CN100396276C (da)
AR (1) AR017979A1 (da)
AT (1) ATE431733T1 (da)
AU (1) AU753519B2 (da)
BE (1) BE1012140A3 (da)
BR (1) BR9907647B1 (da)
CA (1) CA2320182C (da)
CL (1) CL2003002786A1 (da)
CO (1) CO4920246A1 (da)
CY (1) CY1109311T1 (da)
CZ (1) CZ303168B6 (da)
DE (1) DE69940904D1 (da)
DK (1) DK1052974T3 (da)
ES (1) ES2324378T3 (da)
FR (1) FR2774909B1 (da)
HK (1) HK1033809A1 (da)
HU (1) HUP0101564A3 (da)
ID (1) ID26549A (da)
IL (2) IL137550A0 (da)
IT (1) IT1313549B1 (da)
MX (1) MXPA00007681A (da)
MY (1) MY125921A (da)
NO (2) NO329376B1 (da)
NZ (1) NZ506389A (da)
PE (1) PE20000272A1 (da)
PL (1) PL201329B1 (da)
PT (1) PT1052974E (da)
RU (1) RU2214246C2 (da)
SI (1) SI1052974T1 (da)
SK (2) SK287775B6 (da)
TR (1) TR200002299T2 (da)
TW (1) TW457095B (da)
WO (1) WO1999039694A2 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
ATE408612T1 (de) 1996-11-18 2008-10-15 Biotechnolog Forschung Gmbh Epothilone e und f
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
BR0206511A (pt) 2001-01-25 2003-10-21 Bristol Myeres Squibb Company Formulação parenteral para análogos de epotilona
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
CZ20032021A3 (cs) 2001-01-25 2004-05-12 Bristol@Myersásquibbácompany Způsoby podávání analogů epothilonu při léčbě rakoviny
MXPA03006412A (es) * 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
IL156988A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
CA2438598A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Epothilone derivatives for the treatment of refractory tumors
CA2440555A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7030147B2 (en) * 2001-03-19 2006-04-18 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
RU2346686C2 (ru) 2002-01-14 2009-02-20 Новартис Аг Комбинации, включающие эпотилоны и антиметаболиты
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
EP2179745A1 (en) * 2002-06-10 2010-04-28 Novartis AG Combinations comprising epothilones and pharmaceutical uses thereof
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
KR101173510B1 (ko) 2002-08-23 2012-08-21 슬로안-케테링인스티튜트퍼캔서리서치 에포틸론, 이의 중간물질과 유사체의 합성 및 이들의 용도
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TWI291464B (en) 2002-09-23 2007-12-21 Bristol Myers Squibb Co Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
AU2003279911A1 (en) 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Therapeutic formulations
BR0315293A (pt) * 2002-10-15 2005-08-30 Univ Louisiana State Derivados de lactona para o tratamento de hiperparatireoidismo
ATE452888T1 (de) 2002-11-07 2010-01-15 Kosan Biosciences Inc Trans-9,10-dehydroepothilon c und d, analoga davon und verfahren zu deren herstellung
EP1670487A4 (en) * 2003-10-09 2008-05-21 Kosan Biosciences Inc THERAPEUTIC FORMULATIONS
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7655442B2 (en) 2004-01-29 2010-02-02 Eisai R&D Management Co., Ltd. Method for stabilizing macrolide compounds
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
WO2008019820A2 (en) 2006-08-16 2008-02-21 Novartis Ag Crystal form of epothilone b and use in pharmaceutical compositions
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
CN101642453B (zh) * 2009-09-15 2011-03-16 湖南迪诺制药有限公司 一种含有埃坡霉素b的药物制剂
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
US11628137B2 (en) * 2017-09-27 2023-04-18 Novartis Ag Parenteral formulation comprising siponimod

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IL27947A (en) * 1967-05-09 1972-07-26 Weitzman J Method for the production of thermoplastic resin particles and of mixtures of such particles with additives
JPS56115855A (en) * 1980-02-19 1981-09-11 Toyota Motor Corp Method and apparatus for controlling ignition timing of engine
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法および用途
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
DK1186606T4 (da) * 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
WO1997033552A1 (en) * 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs

Also Published As

Publication number Publication date
SK287487B6 (sk) 2010-11-08
TR200002299T2 (tr) 2000-11-21
JP2002502810A (ja) 2002-01-29
HK1033809A1 (en) 2001-09-28
CN1623543A (zh) 2005-06-08
CL2003002786A1 (es) 2005-02-04
US20030203876A1 (en) 2003-10-30
CZ303168B6 (cs) 2012-05-09
WO1999039694A2 (en) 1999-08-12
MXPA00007681A (es) 2003-07-14
PL201329B1 (pl) 2009-03-31
SI1052974T1 (sl) 2009-10-31
CO4920246A1 (es) 2000-05-29
CN1292683A (zh) 2001-04-25
KR100669174B1 (ko) 2007-01-17
US20060127423A1 (en) 2006-06-15
NO20003930D0 (no) 2000-08-03
EP1052974B1 (en) 2009-05-20
BR9907647A (pt) 2000-11-14
CN100396276C (zh) 2008-06-25
US20110124691A1 (en) 2011-05-26
WO1999039694A3 (en) 1999-09-23
AU2722699A (en) 1999-08-23
ITMI990208A1 (it) 2000-08-04
BR9907647B1 (pt) 2014-04-01
ID26549A (id) 2001-01-18
DE69940904D1 (de) 2009-07-02
FR2774909A1 (fr) 1999-08-20
PT1052974E (pt) 2009-08-07
MY125921A (en) 2006-08-30
SK11702000A3 (sk) 2001-01-18
SK287775B6 (sk) 2011-09-05
US20080221065A1 (en) 2008-09-11
BE1012140A3 (fr) 2000-05-02
NO20003930L (no) 2000-10-04
KR20010040534A (ko) 2001-05-15
ES2324378T3 (es) 2009-08-05
CZ20002834A3 (cs) 2000-11-15
IL137550A (en) 2010-06-30
IL137550A0 (en) 2001-07-24
AU753519B2 (en) 2002-10-17
HUP0101564A2 (hu) 2001-11-28
CA2320182C (en) 2008-11-25
FR2774909B1 (fr) 2000-07-28
JP4644364B2 (ja) 2011-03-02
PE20000272A1 (es) 2000-04-17
RU2214246C2 (ru) 2003-10-20
KR20080016756A (ko) 2008-02-21
NZ506389A (en) 2003-07-25
EP1052974A2 (en) 2000-11-22
KR20060002022A (ko) 2006-01-06
PL342629A1 (en) 2001-06-18
IT1313549B1 (it) 2002-09-09
CY1109311T1 (el) 2014-07-02
HUP0101564A3 (en) 2002-06-28
CA2320182A1 (en) 1999-08-12
JP2010090147A (ja) 2010-04-22
NO329376B1 (no) 2010-10-04
AR017979A1 (es) 2001-10-24
TW457095B (en) 2001-10-01
ATE431733T1 (de) 2009-06-15
US20070060627A1 (en) 2007-03-15
NO20100302L (no) 2000-10-04

Similar Documents

Publication Publication Date Title
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
ID27415A (id) Komposisi farmaseutik
NO20005913D0 (no) Legemiddelsammensetning
ID26982A (id) Komposisi farmasi topiramat
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
NO20015175L (no) Farmasöytisk sammensetning
IS5046A (is) Lyfjasamsetningar
FI991485A (fi) Uusi farmaseuttinen koostumus
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ID26720A (id) Komposisi oral
ID26186A (id) Komposisi sampo
ID28694A (id) Komposisi sampo
ID29262A (id) Komposisi farmasi
ID29430A (id) Komposisi herbisida
DE69942892D1 (de) Gaserzeugende zusammensetzung
DE69928862D1 (de) Zusammensetzung
ID27201A (id) Komposisi farmasi
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
ID27150A (id) Sediaan levotiroksin bahan farmasi
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
ID29294A (id) Komposisi farmasi
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
ID25857A (id) Komposisi farmasi
ATE297187T1 (de) Resorcinenthaltende zusammensetzung